Ascend Advanced Therapies

Ascend Advanced Therapies is a gene therapy development partner based in the United Kingdom. Founded in 2021, the company's slogan, "Ascend is a gene therapy development partner with a flexible platform featuring industry-leading analytics," underscores its commitment to innovation and collaboration within the industry. Ascend supports life-science innovators in bringing gene therapy products to patients, boasting a team with deep expertise in gene therapy development and commercialization.

The company has recently secured a $65.90M Series A investment on 09 May 2023 from a distinguished group of investors including 4BIO Capital, Abingworth, Digitalis Ventures, Cathay Health, Deerfield Capital Management, Ajinomoto, DCVC Bio, Petrichor Healthcare Capital Management. This investment highlights the confidence of prominent investors in Ascend's vision and capabilities.

Ascend prides itself on scientific innovation driven by quality and responsibility, aiming to set a new standard in the industry. The company has invested in a world-class analytical toolkit within its flexible and scalable AAV platform of next-gen technologies, all built to find the perfect balance of yield and quality for each process. With a focus on developing the next wave of accessible life-saving therapies, Ascend is poised to make a significant impact in the Biotechnology, Health and Wellness, and Manufacturing sectors.